- Kedrion joined forces with BPL in 2022
- This is the first ever approval for a BPL product in China
- The China Albumin market is the world’s largest
- Launch has commenced in April 2023
Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, has announced that China’s National Institutes for Food and Drug Control (NIFDC) has approved BPL’s human Albumin product for release to the Chinese market. In 2022, Kedrion joined forces with BPL, a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines for the treatment of rare diseases.
As the first ever approval for a BPL product in China, this a major milestone for the company, which from now can ship to the country on a regular basis. China is by far the largest human Albumin market in the world of 627 tons vs global demand of 1,368 tons in 2021.
“We are delighted to be able to provide this product to patients in China,” said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. “Obtaining this important license and full distribution agreement in China reflects strongly on our current plan for global expansion while highlighting our corporate mission of providing plasma-derived products worldwide, supporting both healthcare professionals and patients every day.”
Zhou Xianfeng, Chairman of Board, Hangzhou Jiansheng Medicine Co. Ltd. said, “We are delighted to have partnered with BPL and Kedrion, which are truly committed to making therapies available in all parts of the world by expanding into important new markets such as China.”
Kedrion places a high value on the welfare of those who benefit from its products, as well as the communities and individuals with whom it collaborates, and works on a global scale to broaden access to plasma therapies.
 MRB Reports (MRB Asia Pacific 2021)